SEC Comment Letter for Theriva Biologics, Inc. (TOVX) (CIK 0000894158) (TOVX) — May 15, 2018
Theriva Biologics, Inc. (TOVX) (CIK 0000894158)
Date: May 15, 2018 · CIK: 0000894158 · Accession: 0000000000-18-014999
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-224728
Letter
May 14, 2018 Steven Shallcross Interim Chief Executive Officer and Chief Financial Officer Synthetic Biologics, Inc. 9605 Medical Center Drive, Suite 270 Rockville, MD 20850 Re:Synthetic Biologics, Inc. Registration Statement on Form S-3 Filed May 7, 2018 File No. 333-224728 Dear Mr. Shallcross: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Dorrie Yale at 202-551-8776 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Leslie Marlow
Show Raw Text
May 14, 2018
Steven Shallcross
Interim Chief Executive Officer and Chief Financial Officer
Synthetic Biologics, Inc.
9605 Medical Center Drive, Suite 270
Rockville, MD 20850
Re:Synthetic Biologics, Inc.
Registration Statement on Form S-3
Filed May 7, 2018
File No. 333-224728
Dear Mr. Shallcross:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Dorrie Yale at 202-551-8776 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Leslie Marlow